Organizer(s): Robert E.W. Hancock and Eric D. BrownDate: March 29 - April 02, 2015
Location: Granlibakken Tahoe, Tahoe City, CA, USA
SIGNIFICANCE: The antibiotic era, stemming from the deployment of penicillin, introduced arguably the most successful medicines of all time, impacting dramatically on life expectancy by decreasing childhood and adult deaths from infections, and enabling complex surgeries, transplantations and cancer chemotherapy. However the therapy of infectious diseases is now under severe threat. There has been an explosion of resistance to antibiotics, whereby our entire arsenal of antibiotics is gradually losing effectiveness. This is particularly acute for Gram negative bacteria since there are few new antibiotics or strategies in the development pipeline. In this meeting we will address the major issues and potential solutions to this crisis. INNOVATION: The issues associated with gram-negative resistance, and the design of effective therapeutics, are different and more complicated than those associated with the other major division of bacteria (gram positives). Consistent with the most recent antibiotics are active against the latter class leaving academic and company researchers and physicians to wonder where the next generation of treatments will come from. For this reason, it is essential that these issues are discussed as a distinct problem that has the potential to unravel human medical successes. Here, we will bring together diverse researchers from disciplines ranging from discovery research to drug development and clinical treatment to discuss strategies for addressing this critical issue and proposing routes for innovative solutions.
Scholarship Deadline: December 1 2014
Discounted Abstract Deadline: December 1 2014
Abstract Deadline: January 6 2015
Discounted Registration Deadline: January 27 2015
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
AstraZeneca Pharmaceuticals, L.P.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI115778-01
Funding for this conference was made possible (in part) by 1 R13 AI 115778-01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.